Septo-optic Dysplasia Plus Syndrome
Alejandro Gutierrez-Castillo, Amado Jimenez-Ruiz, Melissa Chavez-Castillo, José Luis Ruiz-Sandoval

1.

Corresponding author: Alejandro Gutierrez-Castillo, alexgtz91@gmail.com

Abstract

Septo-optic dysplasia plus is a rare congenital syndrome characterized by the classic triad of optic nerve hypoplasia, hypothalamic-hypophyseal dysfunction, and midline abnormalities, with associated malformations of cortical development. Clinical manifestations include optic nerve disease, epilepsy, intellectual delay, and endocrine dysfunction.

We present the case of an 18-year-old man with a history of seizures, growth hormone deficiency, and optic nerve disease that was diagnosed with septo-optic dysplasia plus syndrome with characteristic imaging findings.

Categories: Endocrinology/Diabetes/Metabolism, Neurology, Pediatrics
Keywords: septo-optic dysplasia, seizure, optic nerve hypoplasia, schizencephaly, epilepsy, growth hormone deficiency, cortical dysplasia, septum pellucidum agenesis, polymicrogyria, hypoplasia of corpus callosum

Introduction

Septo-optic dysplasia (SOD), also known as “de Morsier’s Syndrome,” was first reported in 1956 by the Swiss neurologist George de Morsier who described the following triad: hypoplasia/dysplasia of the optic nerve, hypothalamic-hypophyseal dysfunction, and midline abnormalities (dysgenesis of corpus callosum and/or septum pellucidum) [1]. Years later, the term SOD-plus was suggested to differentiate SOD with associated malformations of cortical development [2].

Despite the current controversy regarding the definite etiology of this syndrome, the most accepted hypothesis is the vascular disruption sequence, especially [3-4], an anomaly in the proximal trunk of the anterior cerebral artery [4]. Although most of the cases are sporadic, less than 1% of cases have been associated with mutations in the following genes: HESX1, SOX2, SOX3, or OXT2 [5-6].

In Mexico, there is no information available on its epidemiology, however, previous studies in other countries have shown a prevalence of 1.9-5.4 per 100,000 live births and an increasing incidence of 113.3 per 100,000 live births [7]. There is no gender predilection, but a young maternal age seems to be a common risk factor [7-8].

We present the case of a young adult with SOD-plus with associated ophthalmic, neurologic, and endocrine manifestations.

Case Presentation

An 18-year-old male patient was referred to our unit for the management and follow-up of epilepsy diagnosed during childhood. The patient had focal seizures evolving to bilateral tonic-clonic seizures treated initially with valproic acid. Seizures were well-controlled until a year before presentation when the seizure pattern recurred.

His family history was incomplete due to the absence of the father during upbringing. The patient’s mother was 17 years old when she became pregnant. The medical history was relevant for short stature due to growth hormone (GH) deficiency, with no substitution during childhood due to financial limitations.

The general physical examination revealed short stature (133 centimeters) and low weight (45 kilograms) with a body mass index (BMI) of 20.93 (normal BMI: 18.5-24.99). His vital signs were within normal limits. The neurological examination was relevant for complete right eye blindness with atrophy of the right optic nerve and diminished visual acuity in the left eye; a right horizontal nystagmus was found in the neutral position, which worsened with right lateral gaze. Muscle strength was diminished in the left hemibody with ipsilateral hyperreflexia and extensor plantar response.

Magnetic resonance imaging (MRI) reported the following findings:

- Agenesis of the septum pellucidum, which conditioned a "mono-ventricle" appearance and agenesis of the...
anterior portion of the falx cerebri

- Closed-lip schizencephaly in the right frontal-temporal area, associated with generalized cortical dysplasia of the surrounding parenchyma

- Hypoplasia of the corpus callosum

- Polymicrogyric appearance and disposition in the left transitional frontal-parietal area

- Hypoplasia of the pituitary stalk, the optic chiasm, and both optic nerves (Figure 1)

Topiramate was started, with excellent seizure control. Endocrine testing revealed low insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels while the rest of the hypothalamic-pituitary function tests were normal.

As part of seizure evaluation, an electroencephalogram (EEG) was performed; relevant findings included asymmetry of right hemisphere electrical activity and epileptiform discharges with a right-frontal
focus (Figure 2).

FIGURE 2: Electroencephalographic findings
Panel A: Resting state. Asymmetric and asynchronous basal rhythm. Alpha-range frequency of 8 Hz and left theta range of 6 Hz.

Panel B: Hyperventilation stimulation. Increased epileptiform activity. Bifrontal spike-and-wave complexes in the right frontal lobe (red rectangle).

Due to the presence of the characteristic midline abnormalities along with cortical dysplasia, a diagnosis of septo-optic dysplasia plus was made.

Discussion
The term SOD-plus was suggested by Miller in 2000 to differentiate those patients whose global development delay and motor deficits couldn’t be explained by corpus callosum hypoplasia alone and may manifest other underrecognized cortical malformations [2], such as schizencephaly, polymicrogyria, and gray matter heterotopias [9].

A previous case series of 17 patients with SOD found that 6% of the patients met the criteria for classic SOD, 76% of SOD-plus and 18% of SOD-like, with normal septum pellucidum and corpus callosum in the absence of any cortical abnormalities [9]. In our patient, the SOD-plus criteria were met since the three components of the classic triad were described in the presence of schizencephaly and polymicrogyria as the recognized cortical malformations, an association described in 18% of SOD-plus cases [9].

SOD has a wide clinical heterogeneity, from asymptomatic to severe disabling symptoms [1]. The most frequently described clinical manifestations include visual manifestations (85%-90%), intellectual delay (42.5%-60%), epileptic seizures (27.5%-55%), and endocrine disorders (50%-55%) [10-11]. Neurologically, one of the most feared complications is drug-resistant epilepsy, in which focal cortical dysplasia is the most common cause in this population [1]. In this case, imaging confirmed the presence of focal cortical dysplasia, but epileptic seizures were controlled with two drugs.

Most endocrine findings are diagnosed at an early age, with central hypothyroidism (70%) being the most frequent manifestation, followed by GH deficiency (55%), secondary/tertiary adrenal insufficiency (50%), 2018 Gutierrez-Castillo et al. Cureus 10(12): e3727. DOI 10.7759/cureus.3727
and central diabetes insipidus (30%) [11]. In our case, the most important finding was GH deficiency, which conditioned short stature. However, lifelong monitoring is suggested since more hormonal deficits may appear [12].

Conclusions
SOD-plus is a syndrome characterized by the original triad described by de Morsier along with other cortical malformations. A high degree of suspicion is required to make the diagnosis and should be included in the differential diagnosis of young adult patients with a history of ophthalmologic, endocrine, and neurologic abnormalities.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. AlKhateeb M, McLachlan R, Burneo J, Dioso D, Mirsattari S: Six adult patients with septo-optic dysplasia and drug-resistant epilepsy: clinical findings and course. Epilepsy Behav Case Rep. 2017, 8:73-84. 10.1016/j.ebcr.2017.04.001
2. Miller SP, Shevell MI, Patenaude Y, Poulin C, O’Gorman AM: Septo-optic dysplasia plus: a spectrum of malformations of cortical development. Neurology. 2000, 54:1701-1703. 10.1212/WNL.54.8.1701
3. Chiaramonte I, Cappello G, Uccello A, et al.: Vascular cerebral anomalies associated with septo-optic dysplasia. Neuroradiol J. 2013, 26:66-70. 10.1177/1971409130260011
4. Lubinsky MS: Hypothesis: septo-optic dysplasia is a vascular disruption sequence. Am J Med Genet. 1997, 69:235-236. 10.1002/(SICI)1096-8628(19970331)69:3<235::AID-AJMG43316.0.CO;2-X
5. McCabe MJ, Alatzoglou KS, Dattani MT: Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best Pract Res Clin Endocrinol Metab. 2011, 25:115-124. 10.1016/j.beem.2010.06.008
6. Webb E, Dattani M: Septo-optic dysplasia. Eur J Hum Genet. 2010, 18:395-397. 10.1038/ejhg.2009.125
7. Khaper T, Bunge M, Clark I, et al.: Increasing incidence of optic nerve hypoplasia/septo-optic dysplasia spectrum: geographic clustering in Northern Canada. Paediatr Child Health. 2017, 22:445-453. 10.1093/pch/pxx118
8. Garne E, Rissmann A, Addor MC, et al.: Epidemiology of septo-optic dysplasia with focus on prevalence and maternal age - A EUROCAT study. Eur J Med Genet. 2018, 61:485-488. 10.1016/j.ejmg.2018.05.010
9. Alt C, Shevell M, Poulin C, Rosenblatt B, Saint-Martin C, Sour M: Clinical and radiologic spectrum of septo-optic dysplasia: review of 17 cases. J Child Neurol. 2017, 32:797-805. 10.1177/0883073817703000
10. León-Gonzalez M, García-Perenas JI, Puertas-Bordalino D, López-Fino MA, Argente-Oliver J, Cantarín-Extremera V: Natural course of septo-optic dysplasia: retrospective analysis of 20 cases [Article in Spanish] . Rev Neurol. 2012, 54:321-331.
11. Cemergoglu AP, Coulas T, Klein L: Spectrum of clinical presentations and endocrinological findings of patients with septo-optic dysplasia: a retrospective study. J Pediatr Endocrinol Metab. 2015, 28:1057-1063. 10.1515/ijem-2015-0008
12. Koizumi M, Ida S, Shoji Y, Etani Y, Hatsukawa Y, Okamoto N: Endocrine status of patients with septo-optic dysplasia: fourteen Japanese cases. Clin Pediatr Endocrinol. 2017, 26:89-98. 10.1297/cpe.26.89

2018 Gutierrez-Castillo et al. Cureus 10(12): e3727. DOI 10.7759/cureus.3727